NEW YORK (GenomeWeb News) – Exosome Diagnostics has named new members to its scientific advisory board, including John Quackenbush, Bob Carter, Carlos Cordon-Cardo, and Keith Flaherty. Quackenbush is a professor at Dana-Faber Cancer Institute's Department of Computational Biology and Bioinformatics at Harvard University.
Carter is chief of Neurosurgery at the University of California, San Diego; Cordon-Cardo is vice chairman of pathology and a professor of pathology and urology at Columbia University and he is associate director of the Herbert Irving Comprehensive Cancer Center; and Flaherty is director of Developmental Therapeutics at the Massachusetts General Hospital Cancer Center and a lecturer at Harvard Medical School.
Cora Marrett has been confirmed as deputy director of the National Science Foundation by the US Senate. Marrett has been the senior advisor for Foundation Affairs at NSF since early this year, and before that she was assistant director for NSF's education and human resources directorate and in an earlier stint at NSF in the 1990s she was assistant director for social, behavioral, and economic sciences. She also spent six years as the University of Wisconsin's senior VP for academic affairs and four years as vice chancellor for academic affairs and provost at the University of Massachusetts-Amherst.
Proteomics tools company Silicon Kinetics has named John Ervin to be director of its research and development and engineering activities and to serve on its board of directors. It also has appointed Robert Fein to the board.
Ervin has worked at Eksigent, Ultradots, and PerSeptive Biosystems. Fein is a managing director of the Back Bay Management Consulting Group, and he has served as VP of business development at Trex Enterprises, which helped to found PerSeptive Biosystems.
Denator has appointed Martin Nicklasson to its board of directors. Nicklasson formerly was CEO at Astra Zeneca AB, chairman of the board at Astra Tech, and CEO at Swedish Orphan Biovitrum AB.
Affymetrix said this week that Frank Witney has been named president and CEO of the company, taking over for the departing Kevin King. He also will serve on its board of directors.
Witney previously worked at Affymetrix as executive VP and chief commercial officer, and for the past two years as CEO and president of Dionex, which was recently bought by Thermo Fisher Scientific. Witney also was president and CEO of Panomics before it was acquired by Affy, and he was president and COO at Packard BioScience, and president of Drug Discovery Tools at PerkinElmer Life Sciences after it acquired Packard.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.